CQA 206-291 in Parkinson's disease

Ronald Pfeiffer, R. Hofman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. Significant improvement was noted in the treatment groups compared to the placebo group. Adverse effects were generally mild and transient. CQA appears to be an effective, well-tolerated agent in the treatment of Parkinson's disease. Nevertheless, because of laboratory-based toxicity concerns, CQA has been withdrawn from further human study and will not be developed clinically.

Original languageEnglish (US)
Pages (from-to)170-178
Number of pages9
JournalClinical Neuropharmacology
Volume14
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Parkinson Disease
Placebos
Dopamine Antagonists
Dopamine Agonists
Therapeutics
CQA 206-291

Keywords

  • CQA 206-291
  • Dopamine agonists
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

CQA 206-291 in Parkinson's disease. / Pfeiffer, Ronald; Hofman, R.

In: Clinical Neuropharmacology, Vol. 14, No. 2, 1991, p. 170-178.

Research output: Contribution to journalArticle

Pfeiffer, R & Hofman, R 1991, 'CQA 206-291 in Parkinson's disease', Clinical Neuropharmacology, vol. 14, no. 2, pp. 170-178.
Pfeiffer, Ronald ; Hofman, R. / CQA 206-291 in Parkinson's disease. In: Clinical Neuropharmacology. 1991 ; Vol. 14, No. 2. pp. 170-178.
@article{9c6abd6f51ba416380e44fc5e7d9d761,
title = "CQA 206-291 in Parkinson's disease",
abstract = "CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. Significant improvement was noted in the treatment groups compared to the placebo group. Adverse effects were generally mild and transient. CQA appears to be an effective, well-tolerated agent in the treatment of Parkinson's disease. Nevertheless, because of laboratory-based toxicity concerns, CQA has been withdrawn from further human study and will not be developed clinically.",
keywords = "CQA 206-291, Dopamine agonists, Parkinson's disease",
author = "Ronald Pfeiffer and R. Hofman",
year = "1991",
language = "English (US)",
volume = "14",
pages = "170--178",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - CQA 206-291 in Parkinson's disease

AU - Pfeiffer, Ronald

AU - Hofman, R.

PY - 1991

Y1 - 1991

N2 - CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. Significant improvement was noted in the treatment groups compared to the placebo group. Adverse effects were generally mild and transient. CQA appears to be an effective, well-tolerated agent in the treatment of Parkinson's disease. Nevertheless, because of laboratory-based toxicity concerns, CQA has been withdrawn from further human study and will not be developed clinically.

AB - CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. Significant improvement was noted in the treatment groups compared to the placebo group. Adverse effects were generally mild and transient. CQA appears to be an effective, well-tolerated agent in the treatment of Parkinson's disease. Nevertheless, because of laboratory-based toxicity concerns, CQA has been withdrawn from further human study and will not be developed clinically.

KW - CQA 206-291

KW - Dopamine agonists

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0026080446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026080446&partnerID=8YFLogxK

M3 - Article

C2 - 1673089

AN - SCOPUS:0026080446

VL - 14

SP - 170

EP - 178

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -